Home | PHARMAC
Home | PHARMAC
  • Website
  • Application Tracker
  • Schedule
  • About PHARMAC
    • About PHARMAC
    • Your guide to PHARMAC
    • Our history
    • Our people
    • Expert advice
    • PHARMAC's performance
    • Operating policies and procedures
    • Year in review 2018
    • Strategies
  • Medicines
    • Medicines
    • How medicines are funded
    • Medicines information
    • My medicine or medical device has changed
    • Your health
    • Hospital pharmaceuticals
    • New medicines – from development to funding
    • Equity
  • Hospital devices
    • Hospital devices
    • What's happening in each category?
    • PHARMAC's approach to hospital devices
    • Device Advice
    • PHARMAC medical devices forums 2017
  • News
  • Te Whaioranga
    • Te Whaioranga
    • Te Whaioranga 2013 - 2023: Māori Responsiveness Strategy
    • Whānau Ora
    • He Rongoā Pai, He Oranga Whānau
    • One Heart Many Lives
    • Scholarships
    • Hauora Arotahi - Māori health areas of focus
    • Māori Responsiveness Team
  • Pacific
    • Pacific
    • Pacific responsiveness strategy
    • Pacific action plan
  • Tools & resources
    • Tools & resources
    • Pharmaceutical Schedule
    • Annual Procurement Plan
    • Forms
    • Research
    • Print and PDF resources
    • Glossary
    • PHARMAC labelling preferences for prescription pharmaceuticals
  • Information for…
  1. Medicines /
  2. My medicine or medical device has changed /
  3. Oxycodone

See more about this section

Medicines

  • How medicines are funded
  • Medicines information
  • My medicine or medical device has changed
    • Aflibercept
    • Aripiprazole
    • Ciprofloxacin
    • Diabetes meters
    • Erythropoietin alfa
    • Gabapentin
    • Gaucher disease treatment
    • Hepatitis C treatments
    • Insulin pumps
    • Isotretinoin
    • Omeprazole
    • Paracetamol
    • PrEP for HIV prevention
    • Pulmonary arterial hypertension treatments
    • Rivaroxaban
    • Travoprost eye drops
    • Venlafaxine
  • Your health
  • Hospital pharmaceuticals
  • New medicines
  • Equity

Medicines

  • How medicines are funded
  • Medicines information
  • My medicine or medical device has changed
    • Aflibercept
    • Aripiprazole
    • Ciprofloxacin
    • Diabetes meters
    • Erythropoietin alfa
    • Gabapentin
    • Gaucher disease treatment
    • Hepatitis C treatments
    • Insulin pumps
    • Isotretinoin
    • Omeprazole
    • Paracetamol
    • PrEP for HIV prevention
    • Pulmonary arterial hypertension treatments
    • Rivaroxaban
    • Travoprost eye drops
    • Venlafaxine
  • Your health
  • Hospital pharmaceuticals
  • New medicines
  • Equity

Oxycodone

From 1 July 2016, PHARMAC is changing the funded brand and formulation of oxycondone hydrochloride controlled-release tablets

What is changing?

  • Interpharma Pty Ltd’s new brand, formulation and packaging of oxycodone hydrochloride controlled-release 5 mg, 10 mg, 20 mg, 40 mg, and 80 mg tablets (20 tablets per pack) will be fully funded from 1 July 2016.
  • The tablets will be supplied in blisters instead of bottles.
  • The new brand will become Sole Supply from 1 December 2016.

This table summarises the changes.

 CurrentNew brand and formulation
Oxycodone hydrochloride controlled-release 5 mg tablets

OxyContin controlled-release 5 mg tablets
(supplied by Mundipharma)
Pharmacode 2194767

BNM oxycodone controlled-release 5 mg tablets
(supplied by Interpharma)
Pharmacode 2495627

Oxycodone hydrochloride controlled-release 10 mg tablets

Oxycodone controlled-release 10 mg tablets
(BNM) (supplied by Interpharma)
Pharmacode 2452707

BNM oxycodone controlled-release 10 mg tablets
(supplied by Interpharma)
Pharmacode 2495635

Oxycodone hydrochloride controlled-release 20 mg tablets

Oxycodone controlled-release 20mg tablets
(BNM) (supplied by Interpharma)
Pharmacode 2452715

BNM oxycodone controlled-release 20 mg tablets
(supplied by Interpharma)
Pharmacode 2495643

Oxycodone hydrochloride controlled-release 40 mg tablets

Oxycodone controlled-release 40 mg tablets
(BNM) (supplied by Interpharma)
Pharmacode 2452723

BNM oxycodone controlled-release 40 mg tablets
(supplied by Interpharma)
Pharmacode 2495651

Oxycodone hydrochloride controlled-release 80 mg tablets

Oxycodone controlled-release 80 mg tablets
(BNM) (supplied by Interpharma)
Pharmacode 2452731

BNM oxycodone controlled-release 80 mg tablets
(supplied by Interpharma)
Pharmacode 2495678

Information about the change for people taking oxycodone controlled-release tablets

  1. The brand of medicine has changed.
  2. It will work the same as your old medicine.
  3. It has the same amount of active ingredients as your old medicine.
  4. Talk to your doctor, nurse or pharmacist if you have any questions.

Patient info: New brand and formulation of oxycondone hydrochloride controlled-release tablets funded [PDF, 564 KB]

Last updated: 27 June 2017

About this site

  • Sitemap
  • Copyright
  • Disclaimer
  • Privacy statement
  • This site is operated by PHARMAC, the Pharmaceutical Management Agency.

Contact

  • Contact us
  • Twitter - PHARMACnz
  • Facebook - PHARMACnz
  • YouTube - PHARMACgovtnz
  • LinkedIn - Pharmaceutical Management Agency (PHARMAC)
  • Careers
  • Newsfeed

Back to top

New Zealand Government